Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'. (5th May 2018) - Schöffski, P; Wozniak, A; Stacchiotti, S; Rutkowski, P; Blay, J -Y; Lindner, L H; Strauss, S J; Anthoney, A; Duffaud, F; Richter, S; Grünwald, V; Leahy, M G; et al.